Lv1
10 积分 2023-05-30 加入
The peritumor microenvironment: physics and immunity
1个月前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
1个月前
已完结
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
1个月前
已完结
Metabolic barriers to cancer immunotherapy
1个月前
已完结
Immunotherapy for hepatocellular carcinoma
1个月前
已完结
The Relationship between Angiotensin–Neprilysin Treatment, Echocardiographic Parameters, and NT-proBNP Levels in HFpEF Patients with Acute Decompensated Heart Failure
8个月前
已完结
A subset of neutrophils activates anti-tumor immunity and inhibits non-small-cell lung cancer progression
9个月前
已完结
皖公网安备34019202002308
